In our final episode focused on the OX40 pathway and its emerging therapies, Dr. Joy Wan moderates a thoughtful discussion with two leaders from the patient advocacy community. Wendy Smith Begolka, MBS, Chief Program and Mission Officer at the National Eczema Association, and Korey Capozza, MPH, Founder and Executive Director of Global Parents for Eczema Research, share their perspectives on incorporating patient priorities into clinical trials and effectively communicating with patients about new and emerging treatments.

Disclosures:

Joy Wan, MD - Sun Pharmaceuticals – consulting (DMC), Astria Therapeutics – consulting (ad board), Galderma – fellowship funding (paid to Johns Hopkins)

Wendy Smith-Begolka, MBS - Amgen/Kyowa, Kirin, Pfizer, Sanofi  – advisory board honoraria; Arcutis, Incyte, Galderma – speaker fees; Pfizer, Sanofi – research grants

Korey Capozza, MPH - Advisory board honoraria from Amgen, Kyowa Kirin, Incyte, and Pfizer